Log in

291650 CHOOLIP & SCIENCES Inc KRX · South Korea

CHOOLIP & SCIENCES (291650) news

CHOOLIP & SCIENCES Inc is a public biotech or pharmaceutical company listed on KRX under the ticker 291650, recorded under South Korea. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest CHOOLIP & SCIENCES news

We have not published a story on CHOOLIP & SCIENCES yet. When there is news, it will appear here.

Questions about CHOOLIP & SCIENCES

What is the ticker symbol of CHOOLIP & SCIENCES?

CHOOLIP & SCIENCES Inc trades under the ticker 291650 on KRX.

Where is CHOOLIP & SCIENCES listed?

CHOOLIP & SCIENCES Inc is listed on KRX.

Which country or territory is CHOOLIP & SCIENCES listed under?

Our directory records CHOOLIP & SCIENCES Inc under South Korea.

What does CHOOLIP & SCIENCES do?

Our directory classifies CHOOLIP & SCIENCES Inc as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of CHOOLIP & SCIENCES?

The ISIN recorded for CHOOLIP & SCIENCES Inc is KR7291650000.

Does aibio.space cover CHOOLIP & SCIENCES?

aibio.space lists CHOOLIP & SCIENCES Inc among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to CHOOLIP & SCIENCES?

Companies in our directory listed in the same country and business area as CHOOLIP & SCIENCES: BCWORLD PHARM. Co., SAMSUNG BIOLOGICS Co., SK bioscience Co.,Ltd., Epi Biotech Co., Rznomics, Medy-Tox.

Investor discussion: CHOOLIP & SCIENCES

Members talk about CHOOLIP & SCIENCES (291650). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open KRX:291650 on TradingView.

Listing details

CHOOLIP & SCIENCES Inc is a public biotech or pharmaceutical company listed on KRX under the ticker 291650, recorded under South Korea. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
CHOOLIP & SCIENCES Inc
Ticker
291650
Listing
KRX
Country or territory
South Korea
Business scope
Biotechnology
ISIN
KR7291650000
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.